share_log

HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Lowers Price Target to $20

HC Wainwright & Co. Maintains Buy on BriaCell Therapeutics, Lowers Price Target to $20

HC Wainwright & Co.維持對BriaCell Therapeutics的買入,將目標價下調至20美元
Benzinga ·  2023/10/03 12:03

HC Wainwright & Co. analyst Emily Bodnar maintains BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and lowers the price target from $25 to $20.

HC Wainwright&Co.分析師Emily Bodnar維持BriaCell Treateutics(納斯達克:BCTX)的買入,並將目標價從25美元下調至20美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論